Hodges Capital Management Inc. Purchases Shares of 14,709 G1 Therapeutics Inc (GTHX)

Hodges Capital Management Inc. purchased a new stake in G1 Therapeutics Inc (NASDAQ:GTHX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 14,709 shares of the company’s stock, valued at approximately $292,000. Hodges Capital Management Inc. owned approximately 0.05% of G1 Therapeutics as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the stock. FMR LLC bought a new stake in G1 Therapeutics in the second quarter valued at $34,093,000. Emerald Advisers Inc. PA lifted its position in G1 Therapeutics by 2.5% during the third quarter. Emerald Advisers Inc. PA now owns 728,433 shares of the company’s stock valued at $18,131,000 after buying an additional 17,977 shares during the period. Chartwell Investment Partners LLC lifted its position in G1 Therapeutics by 5.0% during the third quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock valued at $2,303,000 after buying an additional 4,388 shares during the period. Vanguard Group Inc. purchased a new position in G1 Therapeutics during the second quarter valued at $1,291,000. Finally, Goldman Sachs Group Inc. purchased a new position in G1 Therapeutics during the second quarter valued at $1,144,000. Institutional investors and hedge funds own 43.25% of the company’s stock.

G1 Therapeutics Inc (NASDAQ GTHX) opened at $19.38 on Friday. G1 Therapeutics Inc has a 52-week low of $12.04 and a 52-week high of $28.67.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. analysts forecast that G1 Therapeutics Inc will post -2.72 EPS for the current year.

Several brokerages have commented on GTHX. Zacks Investment Research lowered G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. JPMorgan Chase & Co. raised their price objective on G1 Therapeutics to $30.00 in a research report on Monday, February 5th. BidaskClub lowered G1 Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 3rd. BTIG Research began coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $38.00 price objective for the company. Finally, Cowen reissued a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. G1 Therapeutics presently has a consensus rating of “Buy” and an average target price of $32.80.

In related news, Director Fredric N. Eshelman purchased 250,000 shares of the stock in a transaction dated Monday, November 13th. The stock was purchased at an average price of $19.73 per share, with a total value of $4,932,500.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Rajesh Malik sold 3,776 shares of G1 Therapeutics stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $22.96, for a total value of $86,696.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 546,682 shares of company stock valued at $10,865,628.

COPYRIGHT VIOLATION WARNING: This report was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://stocknewstimes.com/2018/02/11/hodges-capital-management-inc-purchases-shares-of-14709-g1-therapeutics-inc-gthx.html.

About G1 Therapeutics

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Institutional Ownership by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply